The Board and CEO of Emotra AB herewith present the year-end report for the financial year 2020. 210224 Year-end report 2020 EN
An article on the first study on the connection between hyporeactivity and increased risk of depression relapse has been published... 210215 - Emotra- PM - Publication in BMC Psychiatry
As for many other companies, the Covid-19 situation has been challenging for Emotra. 201229 - Emotra - PM - Emotra, overview for 2021
Today, Emotra is proud to announce that a manuscript that reports the findings from our first study.... 201221 - Emotra- PM - First relapse study accepted for publication in BMC Psychiatry
The Board of Directors and the CEO of Emotra AB hereby present the interim report for the first nine months of 2020. 201126 Interim report Jan- Sept 2020
Notice is hereby given that an extraordinary general meeting of shareholders in Emotra AB (publ), 556612-1579, will be held at 11 am on Friday December 4.... 201120 - Emotra- PM - Notice of EGM
Today, October 26, 2020, Emotra AB (“Emotra” or “the Company”) published the results of the TO 2020 series subscription-warrant conversion. 201026 - Emotra - PM - Result subscription warrants of TO 2020 series
Daniel Poté, Emotra AB’s CEO (“Emotra” or “the Company”) has notified that he intends to exercise his right to convert 50% of his subscription warrants in connection with the second phase of Emotra’s rights issue. 201016 - Emotra - PM - CEO Daniel Poté intends...
Emotra has just entered an agreement with Mediq Innovation Experts GmbH (“Mediq”) concerning a future establishment on the German market. 201009 - Emotra - PM - Emotra enters agreement to develop the german market
Claes Holmberg, the chairman of the board of Emotra AB (“Emotra” or “the Company”) has notified that he intends to exercise his right to convert subscription warrants..... 201008 - Emotra - PM - Chairman Claes Holmberg intends to convert subscription...